|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03309 C-MER MEDICAL
Nominal 
1.290 0.000 (0.000%) | 2025/12 - Final HKD(K$) | %Chg (Compare to Final) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Turnover | 1,946,712 | 1.754% | 1,913,162 | 1,923,964 | 1,731,903 | 1,112,577 |
| Cost of Sales | (1,343,042) | -3.067% | (1,385,543) | (1,305,002) | (1,284,206) | (754,349) |
| Gross Profit | 603,670 | 14.414% | 527,619 | 618,962 | 447,697 | 358,228 |
| 2025/12 - Final HKD(K$) | %Chg (Compare to Final) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (647) | -99.496% | (128,442) | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (581) | -40.410% | (975) | 3,164 | 37,799 | 10,652 | |
| Profit / (Loss) before Taxation | 155,520 | -- | (76,221) | 124,269 | (11,227) | 26,875 | |
| Taxation | (44,346) | 38.180% | (32,093) | (37,934) | (34,998) | (10,645) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (10,808) | -59.745% | (26,849) | (24,337) | 24,350 | 5,631 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 100,366 | -- | (135,163) | 61,998 | (21,875) | 21,861 | |
| 2025/12 - Final HKD(K$) | %Chg (Compare to Final) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Net Finance Costs / (Income) | 11,370 | 25.151% | 9,085 | (1,768) | 12,544 | 8,520 |
| Depreciation & Amortisation | 198,763 | -6.956% | 213,623 | 220,990 | 224,034 | 148,581 |
| Directors' Emoluments | -- | -- | 11,464 | 11,966 | 12,777 | 14,079 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 8.330 | -- | -10.960 | 4.940 | -1.770 | 1.900 |
| DPS (cts) | 3.000 | -- | 2.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | 36.014% | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.230 | 0.288 | 0.134 | 0.126 |
| NBV per share ($) | 1.464 | -- | 1.396 | 1.470 | 1.473 | 1.157 |
| Remarks: | Real time quote last updated: 10/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 100,366 |
| %Change | -- |
| EPS / (LPS) | HKD 0.083 |
| NBV Per Share ($) | HKD 1.464 |